PF-Atlas › Treatments › OSK Partial Reprogramming of AEC2s
OSK Partial Reprogramming of AEC2s
Inhaled LNP-mRNA OSK resets epigenetic age of AEC2s — treats root cause
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Preclinical
Evidence level
Level 3 (Preclinical)
Mechanism class
Inhaled LNP-mRNA OSK resets epigenetic age of AEC2s — treats root cause
Timeline
5-8 years
Risk profile
Medium-High
Developer
Altos Labs / Shift Bio
Key researchers
D. Sinclair
Overview
AEC2 Horvath clock 10-15 years advanced in IPF. OSK reversal in optic nerve (Nature 2023). 2025 review: organ-specific dedifferentiation and epigenetic remodeling demonstrated in vivo. OSKM+TERT combination shows enhanced anti-aging effects. No AEC2-specific data yet but pathway proven.
How OSK Partial Reprogramming of AEC2s fits into IPF treatment
OSK Partial Reprogramming of AEC2s is classified as Level 3 (Preclinical) at the Preclinical stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about OSK Partial Reprogramming of AEC2s for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.